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Background: Transcatheter Aortic Valve Implantation (TAVI) is a rapidly evolving strategy for therapy of aortic stenosis. We describe the experience 
and learning curve of the first 250 patients in Vancouver, Canada.
Methods: Patients underwent TAVI by TransFemoral [(TF), 66%] or TransApical [(TA,), 34%] routes using Edwards balloon expandable valves. The 
experience was divided into the First Half (FH, patients 1-125) and Second Half (SH, patients 126-250).
Results: The mean age was 83.2±8 years. The mean Society of Thoracic Surgery Score (STS) was 9.8 ± 5.8 - FH 10.9 vs. SH 9.1 (p=0.08). The 
procedural success rate in the FH was 92.8%, improving to 96.8% in the SH. The TF procedural success improved - FH 90.2% to SH 97.6%. The TA 
procedural success was similar - FH 97.7% to SH 95.3%. The overall 30-day mortality was 10.4%, improving from FH 13.6% to SH 6.4%. In the TF 
cases, 30 day mortality improved by 55% [10.9% to 4.9%]. In the TA cases, 30 day mortality improved by 56% [20.9% to 9.3%]. In-hospital stroke 
occurred in 3.2% (FH 2.4% vs. SH 4.0%). The overall need for a new permanent pacemaker was 6.0% (FH 7.2% vs. SH 4.8%). Regarding valve 
function, aortic valve areas decreased mildly during follow-up (mean decrease post procedure to 24 months, 0.2±0.35cm2, p=0.04), but the mean 
gradient increase was not significant (mean increase post procedure to 24-months 1.5±0.72mmHg, p=0.68) [see graph].
Conclusions: TAVI outcomes improve with experience and device development.
